Open-label Trial of Stelara (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients.
Latest Information Update: 16 May 2014
Price :
$35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Pyoderma gangrenosum
- Focus Therapeutic Use
- Acronyms SPG
- 16 May 2014 New trial record